Form 4 for OLMA Olema Pharmaceuticals, Inc.
Accepted 2026-07-27 19:30:05 ET · period of report 2026-07-23 · accession 0001831410-26-000008 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2026-07-27 19:30 | 2026-07-23+ | OLMA | Harmon Cyrus | Dir | S - Sale | $11.65 | -25.0K | 702.8K | -3% | -$291.2K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-07-23 | S | D | 12,500 | $11.58 | 715,270 | D | — | — | (F1) The weighted average sale price for the transaction reported was $11.579, and the range of prices were between $11.52 and $11.675. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided. |
| 2 | Common | Common Stock | 2026-07-24 | S | D | 12,500 | $11.71 | 702,770 | D | — | — | (F2) The weighted average sale price for the transaction reported was $11.714, and the range of prices were between $11.70 and $11.775. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided. |